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Abstract
Rationale and objective
Endothelial progenitor cells (EPCs) play a role in vascular repair, while circulating endothe-
lial cells (CECs) are biomarkers of vascular damage and regeneration. Statins may promote
EPC/CEC mobilization in the peripheral blood. We evaluated whether pre-procedural expo-
sure to different lipid-lowering drugs (statins±ezetimibe) can acutely increase levels/activity
of EPCs/CECs in patients with stable coronary artery disease (CAD).
Methods
In a planned sub-analysis of the Rosuvastatin For REduction Of Myocardial DamagE During
Coronary AngioplastY (REMEDY) trial, 38 patients with stable CAD on chronic low-dose
statin therapy were randomized, in a double-blind, placebo-controlled design, into 4 groups
before PCI: i. placebo (n = 11); ii. atorvastatin (80 mg+40 mg, n = 9); iii. rosuvastatin (40 mg
twice, n = 9); and iv. rosuvastatin (5 mg) and ezetimibe (10 mg) twice, (n = 9). At baseline
and 24 h after treatment–before PCI–, patients underwent blinded analyses of EPCs [colony
forming units-endothelial cells (CFU-ECs), endothelial colony-forming cells (ECFCs) and
tubulization activity] and CECs in peripheral blood.
Results
We found no significant treatment effects on parameters investigated such as number of
CECs [Median (IQR): i. 0(0), ii. 4.5(27), iii. 1.9(2.3), iv. 1.9(2.3)], CFU-ECs [Median (IQR):
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Conclusions
In this study, we found no evidence of acute changes in levels or activity of EPCs and CECs
after high-dose lipid-lowering therapy in stable CAD patients.
Introduction
Stem/progenitor cell transplantation or mobilization are emerging as promising new treat-
ments for heart failure and myocardial infarction [1]. Endothelial progenitor cells (EPCs) are
rare progenitor cell subsets originated in the bone marrow, which are mobilized upon specific
stimulation [2–4], then homing to target tissues where they are involved in endothelial repair
or remodeling, as well as in post-natal neo-vasculogenesis [5]. EPCs may contribute to cardiac
and vascular repair [6–8]. EPCs also appear to promote cardioprotection and cytoprotection
by releasing paracrine factors, such as vascular endothelial growth factor (VEGF), granulo-
cyte-colony stimulating factor (G-CSF), stem cell-derived factor (SDF)-1α and insulin growth
factor (IGF)-1 [9, 10].
Among their so called “pleiotropic effects”, independent of low-density lipoprotein (LDL)
reduction, statins have been shown to efficiently increase levels of EPCs in patients with coro-
nary artery disease (CAD) [11] and in patients with chronic heart failure [12], and to improve
the proliferative capacity of EPCs, in a way similar to VEGF [11, 13, 14]. Such effects have
been ascribed to the regulation of stem/EPC gene expression and function [15, 16]. Treatment
with statins may also inhibit stem cell apoptosis and increase their proliferation [17]. Statins
inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a rate-limiting
enzyme catalyzing the conversion of HMG-CoA to mevalonic acid. In addition to improving
lipid profile by reducing LDL cholesterol levels, statins reduce the incidence of myocardial
infarction after percutaneous coronary intervention (PCI) [18, 19]. In the randomized
ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) RECAP-
TURE trial, reloading with high-dose atorvastatin has been reported to improve clinical out-
comes of patients on chronic statin therapy undergoing PCI [20]. Other described acute effects
of statins in the setting of PCI [21] include the modulation on endothelial function, inflamma-
tion and thrombosis, with mechanisms not completely understood [22]. One hypothesis is
that pre-procedural intensive statin treatment activates cardioprotection and vascular repair
by stimulating proliferation, mobilization and homing of EPCs, with subsequent augmenta-
tion of circulating and cardiovascular tissue-resident EPCs, in a manner independent of cho-
lesterol synthesis [23].
We tested this hypothesis in the setting of a pre-specified subanalysis of patients enrolled in
the Rosuvastatin for REduction of Myocardial damagE and systemic inflammation During
coronary angioplasty (REMEDY) trial, specifically investigating whether acute statin treatment
before PCI is accompanied by (and is therefore possibly mechanistically linked to) an increase
in CEC/EPC levels and functional activities.
Lipid-lowering agents, CECs and EPCs
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Materials and methods
Study population and design
The present report derives from a pre-defined single-institution (“G. d’Annunzio” University
Cardiology Division at Chieti, Italy) substudy of the Rosuvastatin For REduction Of Myocardial
DamagE During Coronary AngioplastY (REMEDY) clinical trial.
REMEDY (Eudract Number: 2009-013622-17; ClinicalTrials.gov
Identifier = NCT02205775) was a prospective, multicenter, double-blind, randomized clinical
trial, examining consecutive patients with stable CAD or a previous acute coronary syndrome
(ACS) off the acute phase, undergoing elective percutaneous coronary intervention (PCI) with
stenting. The design of the study, as well as of its main substudies, have been published [23].
The primary results of the REMEDY trial have not been published and likely will not, because,
when less than half the projected patients had been included, the sponsoring company with a
unilateral decision decided to interrupt the funding. Therefore, only two centers, Chieti and
Naples, continued the mechanistic substudies with their own resources, only relying upon the
availability of the randomization treatments still available.
The design of the present substudy is illustrated in Fig 1. Inclusion criteria, as for the main
REMEDY trial [23], were: 1) stable coronary artery disease (CAD) with inducible myocardial
ischemia and indication to coronary angiography; or 2) non-ST-segment (NSTE) ACS or
STEMI deemed to require an invasive strategy, but with stabilized markers of myocardial
necrosis (CK-MB or troponins, with variation <20% in 2 consecutive measurements obtained
at6 h time distance before PCI, according to the second universal definition of periproce-
dural myocardial infarction [24]). Exclusion criteria, as in the main REMEDY trial, were:
STEMI or NSTE-ACS with high-risk features warranting emergency coronary angiography:
any increase in liver enzymes (aspartate amino transferases/alanine amino transferases)
ascribed to liver dysfunction at baseline; left ventricular ejection fraction <30%; renal failure
with creatinine >2 mg/dL; history of liver or muscle disease; ongoing treatment with high-
dose statins (atorvastatin 80 mg/day or rosuvastatin 40 mg/day); pregnancy and lactation.
Patients were randomized into 4 treatment groups:
1. standard background treatment (performing PCI on the background of standard treatment,
without any change of the therapy received, according to local practice), and placebo twice
immediately before PCI;
2. standard background treatment plus atorvastatin 80 mg + 40 mg before PCI (same daily
dosage as in the ARMYDA study [25–27]);
3. standard background treatment plus rosuvastatin 40 mg twice before PCI;
4. standard background treatment + rosuvastatin 5 mg + 10 mg ezetimibe twice before PCI
(dosages expected to be equipotent, in terms of LDL cholesterol reduction, to the rosuvasta-
tin regimen, but testing a largely HMG-CoA reductase inhibition-independent way of
reducing LDL cholesterol).
Due to the acute nature of the interventions, no changes in plasma lipids were expected as
the result of treatment, and therefore were not sought. No independent measures of treatment
intake were therefore obtained. However the intake of the double-blinded study medications
was witnessed by the investigators responsible of their administration.
Informed consent was obtained from all patients. This specific substudy, in addition to the
main study, was approved by the local Ethics Committee (Full name: “Comitato Etico delle
Province di Chieti e Pescara e dell’Universita’ degli Studi "G. d’Annunzio" di Chieti-Pescara”).
Lipid-lowering agents, CECs and EPCs
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All participants provided their written informed consent to participate in this study. The Eth-
ics Committee approved this consent procedure. Data obtained were managed blindly.
According to the protocol, patients were treated before intervention with aspirin (100 mg/
day) and clopidogrel (75 mg/day if on chronic (>3 day) treatment; or given a 300–600 mg
loading at least 6 h before the procedure if previously untreated with a P2Y12 inhibitor. Proce-
dural success was defined as a residual stenosis <30% diameter. After PCI, aspirin (100 mg/
day) was continued indefinitely, whereas clopidogrel (75 mg/day) was administered for at least
1 month (6–12 months in patients treated for ACS or receiving drug-eluting stents). After the
intervention, all patients were treated with atorvastatin (40 mg/day), irrespective of the initial
randomization assignment.
At the time of randomization and at the time of treatment reload immediately before the
diagnostic angiography and PCI, peripheral blood was collected to measure CEC levels and
Fig 1. Study design of the REMEDY-EPC early substudy. Coronary artery disease (CAD) patients candidate for an elective percutaneous coronary
interventions (n = 60) were screened, Forty-eight of them, providing written informed consent, were enrolled and randomly allocated to 4 treatment
strategy groups comprising placebo or 3 lipid-lowering treatments, as illustrated. The final analysis consisted of n = 38 patients due to some missing
sampling (indicated by *), as illustrated. Sampling for the identification and quantification of endothelial progenitor cells (EPCs) and circulating endothelial
cells (CECs) were performed at the time of randomization (sample R), and 1 hour before the diagnostic angiography and PCI, at time of treatment reload
(placebo or lipid-lowering treatments, sample T0).
https://doi.org/10.1371/journal.pone.0172800.g001
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EPC levels and functional activity (see below). In addition, plasma lipids (total cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides, to derive low-density lipoprotein
(LDL) cholesterol according to the Fredrikson formula), were measured before treatment; cre-
atine kinase (CK), CK-MB (mass), troponin-I (mass), and myoglobin were assayed–before
and after the acute treatment–with standard centralized laboratory assays. The upper limits of
normal (ULN) were defined as the 99th percentile of a normal population with a<10% total
imprecision according to the Joint European Society of Cardiology/American College of Car-
diology Universal Myocardial Infarction definition [24]. C-reactive protein (CRP) levels were
also measured at the same time points. CRP were assayed by the Kriptor ultrasensitive immu-
nofluorescent assay (Brahms, Hennigsdorf, Germany), with a detection limit of 0.06 mg/L.
Endpoint definitions. The primary objective of the REMEDY-EPC early substudy was to
compare changes of CEC levels and EPC levels and functional activities essential for vasculo-
genesis (early and late EPC colony formation, proliferation, migration and tube formation)
resulting from the acute randomization treatments before PCI.
Collection and processing of peripheral blood for CEC and EPC levels
To monitor changes in CEC and EPC levels, 12 mL peripheral blood (the minimum amount
required to obtained a visible 3-layer stratification for mononuclear cell isolation) were col-
lected into ethylenediaminetetraacetic acid (EDTA)-treated tubes (4 tubes/patient) at the time
of randomization (sample R), and at the time of treatment reload (sample T0), this latter per-
formed 1 h before diagnostic angiography and PCI. Blood samples were maintained in EDTA-
treated tubes at +4˚C, and used within 5 h for mononuclear cell (MNC) isolation and assays of
functional activities.
CEC/EPC isolation. All culture methods to identify CEC/EPC levels require a prelimi-
nary step of mononuclear cell isolation from peripheral blood. Therefore, peripheral blood
mononuclear cells were isolated from 12 mL of peripheral blood by gradient centrifugation
using Ficoll-Paque PLUS (Amersham). Twelve mL of peripheral blood (in 4 ethylenediamino-
tetraacetic acid (EDTA)-containing vacutainers [BD Vacutainer Eclipse, 21 G x 1-1/4”, 0.8 x
32 mm), in EDTA (2 mg/mL) tubes (BD K2E EDTA, Becton Dickinson Biosciences (BD), San
Jose, CA, USA] were mixed with 1 part of phosphate-buffered saline (PBS). An equal volume
of Ficoll was placed in a 50 mL Falcon tube, and the blood-PBS mixture was carefully stratified
onto Ficoll. The tube was then centrifuged at 400 x g at 20˚C for 35 min. Three layers were
obtained at the end of centrifugation: a. an upper layer, containing plasma + PBS; b. a middle
layer, containing monocytes and lymphocytes; c. a lower layer, containing Ficoll, neutrophils
and erythrocytes. The middle layer was gently aspirated and placed in a new 50 mL Falcon
tube, to which 25 mL cold PBS were added, and then further centrifuged at 400 x g for 5 min.
The upper layer was then snap-frozen at -80˚C, in 3 mL aliquots, in cryovials for further bio-
chemical determinations (for adhesion molecules, growth factors, and cytokines, not the sub-
ject of this report). The pellet was then resuspended in 30 mL PBS/5% fetal calf serum,
centrifuged at 400 x g for 5 min, washed again, then used for colony forming units-endothelial
cells (CFU-EC) and the isolation of late outgrowth colonies.
CFU-EC isolation and quantification. CFU-EC also known as CFU-Hill [28]) were cul-
tured using the EndoCult1 Liquid Medium kit (Stem Cells Inc., Vancouver, Canada), accord-
ing to the manufacturer’s instructions and as described in detail previously [29]. The cells
organize in small clusters of central rounded cells, with radiating spindle-shaped cells that dis-
appear from the 10–14 day on (Fig 2, panel A). At day 5 after plating in fibronectin-coated
24-well plates, clusters were counted in 8 randomly selected high-power (20x magnification)
fields.
Lipid-lowering agents, CECs and EPCs
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Isolation and quantification of late outgrowth colonies. Late outgrowth colonies, also
called endothelial colony forming cells (ECFCs), were isolated as previously described [30].
Briefly, 1 × 106 peripheral blood mononuclear cells were plated onto fibronectin-coated
6-well plates, and cultured in endothelial cell basal medium (EBM)-2 (Cambrex Bio Science
Walkersville Inc., Walkersville, MD, USA), with Endothelial Cell Growth Medium (EGM™)-
2 supplement (Cambrex) for 15 days. The culture medium was changed first on day 4, and
then every 2 days. With this culture system, attaching cells rapidly assume an endothelial-
like shape, and starting from days 3–6 of culture, proliferate in clusters or small colonies
made-up of a central core of rounded cells surrounded by radiating spindle-shaped cells.
Starting from days 10–14, cells also organize in large colonies with a cobblestone appearance,
which are considered endothelial colonies, and become confluent starting from days 21 (Fig
2 panel B). Clusters were visualized under an inverted microscope every 3 days starting from
days 7–14, and counted, at days 14 and 21 after plating, in 8 randomly selected 10x magnifi-
cation fields.
Tube formation assay
The tube formation assay was performed on late ECFCs collected at days 21, with a minimal
volume of Matrigel in 96-well plates (BD), which allows the formation of both tubules and a
vascular network. After detachment from the plates at day 21 with the use of 0.25% trypsin,
1 × 104 late ECFCs were placed on a matrix solution with EGM-2 microvascular (MV)
medium, and incubated at 37˚C for 16 h. Tube formation was monitored with an inverted
phase-contrast microscope (Leica, Wetzlar, Germany), and picture taken by an attached digital
output Olympus camera. Tube formation indices (including tube areas, tube length, and tube
number) were quantified with the National Institutes of Health (NIH) version 1.49 Image
software.
Fig 2. Colony forming units-endothelial cells and late endothelial colony forming cells. Representative images of colony forming units-endothelial
cells or CFU-Hill (A) and late endothelial colony forming cells or ECFCs (B) in patients at time of treatment reload.
https://doi.org/10.1371/journal.pone.0172800.g002
Lipid-lowering agents, CECs and EPCs
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Multi-color flow cytometry
The first 3 mL of peripheral blood withdrawn were discarded and not used for the flow
cytometry analysis to avoid the effects of the venipuncture damage on CEC numbers. Every
first mL of the blood sampling was instead used to determine the sample leukocyte count, in
order to assess total white cell count and lymphocyte absolute count by using double plat-
form counting.
Instrument setting. Once set, the performance, stability, and data reproducibility of the
flow cytometer were daily checked in real time using the BD™ Cytometer Setup and Tracking
(CS&T) Quality Control Module, and further validated by the acquisition of Spherotech 8
Rainbow Beads peaks (Spherotec. Lake Forest, IL, USA), as well as of CS&T bright beads [31].
Afterwards, stabilization of the laser lamp was done for a period of 30 min.
Reagents/antibodies panel. CECs were identified as CD34bright/CD45-/CD144+/CD146+
events, together with DNA staining and dead cell exclusion, by using an already established
panel of reagents [31]. To improve standardization, liquid reagents for the panel and the
respective control tube (Figs 3 and 4) were lyophilized as described [31]. A single lot of lyophi-
lized reagent tubes was used for the entire study.
Sample staining. For each sample, 20 x 106 leukocytes were processed within 4 h from
blood collection, as described [32]. Briefly, the sample volume containing 20 x 106 leukocytes
underwent an erythrocyte lysis step through the addition of 45 mL of Pharm Lyse solution
(BD) for 15 min at room temperature under gentle agitation, as per the manufacturer’s
instructions. Samples were then centrifuged (400 x g for 10 min at room temperature) and
washed by adding 2 mL of staining buffer, containing bovine serum albumin (BD). Surface
staining was carried out by adding the pellet of each sample to the re-hydrated lyophilized
cocktail of reagents. To this, 1 μM Syto-16 (Thermo Fisher Scientific, Waltham, MA, USA)
and V450-conjugated anti-CD144 (i.e. conjugated with fluorochrome V450, with 406 nm exci-
tation and 450 nm emission) were added as a liquid drop to each panel tube (Fgures 3 and 4).
Samples were incubated in the dark for 30 min at 4˚C, washed into 2 mL of staining buffer
with bovine serum albumin, and resuspended in 1.5 mL of FACSFlow buffer (BD).
Data acquisition. A minimum of 2 x 106 and a maximum of 4 x 106 events/sample with
lymph-monocyte morphology were acquired by flow cytometry with a FACSCanto apparatus
(BD) at a “medium” flow rate (60 μL/min of sample). A threshold combination was used on
the forward scatter (FSC) and the fluorescein isothiocyanate (FITC) (Syto16) channels to get
rid of very small and non-nucleated events. The specificity of anti-CD144, anti-CD146 and
anti-VEGFR2 bindings were assessed with the use of isotype-matched controls at the same
Fig 3. Flow cytometry specificities and reagents. Reagents composing the lyophilized panel are evidenced in bold face.
Other reagents added to the basic panel are listed in plain fonts. *Catalog number of the lyophilized combination. Abbreviations:
PE = R-phycoerythrin; 7-AAD = 7-AminoActinomycin D; Cy7 = PE-Cyanine; APC-H7 = Allophycocyanin-Hilite®7; BD = Becton
Dickinson Biosciences (San Jose, CA, USA).
https://doi.org/10.1371/journal.pone.0172800.g003
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concentration and from the same manufacturers of the respective specific antibodies. Com-
pensations were done using CompBeads (BD) and single-stained fluorescent cells. Carryover
between samples was prevented by appropriate instrument cleaning at the end of each sample
acquisition.
Gating strategy. Events displaying the typical lymph-monocyte morphology were first
selected in a forward scatter (FSC) versus side scatter (SSC) plot. Next, dead cells were
excluded (on a 7-amino-actinomycin D (7-AAD)/FSC dot plot) on the basis of their positivity
to 7-AAD, and nucleated events were gated. The aforementioned 3-gating plots were inter-
sected, and cells resulting from this logical combination characterized by lymph-monocyte
morphological features, being also alive and nucleated, were then analyzed for CD45 and
CD34 expression on a CD45/CD34 dot plot. The whole CD34+ cell compartment was identi-
fied, and two subpopulations, displaying different levels of CD34 surface expression, were
identified and gated separately. These were CD34+ cells, which are CD45dim and represent
the hematopoietic stem cell compartment; and a CD34 bright population, which resulted to be
CD45 negative (CD45-). Both the hematopoietic stem cell (HSC) and the CD34bright/CD45-
cell populations were then analyzed for the expression of CD144, CD146 and CD309, on
CD144/CD34, CD146/CD34 and CD309/CD34 dot plots, and compared with their respective
control tube dot plots, containing the isotype controls.
Data analysis. Data were centrally collected and analyzed by a single operator by using
the FACSuite v1.04 (BD) software. To ensure the correct identification of negative and positive
populations, cells were plotted using a dot-plot bi-exponential display. In order to assess non-
specific fluorescence, both fluorescence minus one (FMO, a type of control employed in exper-
iments using multiple dyes, in which all labels are included except the one suspected to give
spectral overlap) and isotype controls in combination with all the remaining surface reagents
present in the panels were used [33, 34].
Fig 4. Composition of the flow cytometry panel and control tubes. Reagents composing the lyophilized panel are evidenced in bold face. Other
reagents added as liquid drop in to the basic panel are listed in plain fonts. Abbreviations: PE = R-phycoerythrin; 7-AAD = 7-AminoActinomycin D;
Cy7 = PE-Cyanine 7; APC = Allophycocyanin = APC; APC-H7 = Allophycocyanin-Hilite®7.
https://doi.org/10.1371/journal.pone.0172800.g004
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Counting formula. CECs and hematopoietic stem cell numbers were calculated by a
dual-platform counting method, and absolute numbers were obtained by using the already
reported formula [31].
Statistical analyses
All parameters of in vitro angiogenesis and clonogenic activity, as well as antigen expression
measured before and after treatments were compared with the Wilcoxon matched-pairs signed
ranks test to evaluate possibly significant changes. Baseline characteristics among the interven-
tion groups were compared using the Fisher’s exact test for categorical variables, and the Wil-
coxon signed-rank test for continuous ones. The Kruskal-Wallis test was then used to assess
whether the post-pre difference in each parameter differed by treatment group, gender, smok-
ing, history of cardiovascular diseases (CVD), hypercholesterolemia, dyslipidemia, diabetes,
hypertension, and diagnosis of stable CAD.
As a secondary analysis, Spearman’s correlation coefficients were used to explore the rela-
tionships between between couples of post-pre differences for each parameter. Statistical sig-
nificance was defined as a two-sided p-value <0.05 for all analyses. These were carried out
using the Stata 2013 version 13.1 software (Stata Corp., College Station, Texas, USA). A formal
sample size calculation to detect differences in the various study arms was not performed, due
to the lack of precise data on the topic in the literature. All analyses are therefore to be consid-
ered exploratory and underpowered, and p-values are therefore not reported. Patients whose
blood sample was not enough for both analysis (flow cytometry and colony assay) were not
included in the study and the blood was discarded in such cases.
Results
Patient characteristics
Patient recruitment for this study started in November 2011 and was completed in November
2013. A total of 60 patients, candidates for coronary angiography were screened. Of these, 12
patients did not give their consent to the study and were therefore withdrawn from further
analysis. For 10 patients, blood samples sufficient for EPC and CEC analyses at both time
points were not available. Thus, 38 patients were finally included and analyzed. Their mean
age was 71 ± 5 years, and 74% were men. Of these 38 patients, 9 received atorvastatin 80 mg
+ 80 mg, 9 received rosuvastatin 40 mg + 40 mg, 9 received rosuvastatin 5 mg and ezetimibe
10 mg, and 11 received placebo (Fig 1).
Patient characteristics are depicted in Fig 5. 50% of the study population had a previous
ACS off the acute phase. There were no statistically significant between-group differences in
any of the group characteristics, and no differences were also found between patients who
received any lipid-lowering agents, however combined, and those who received placebo.
Effects of treatments on indices of myocardial damage, and side effects
Due to the short course of treatment, no effects on plasma lipids were hypothesized, and not
actually investigated. No changes in any of the other laboratory parameters assessed to moni-
tor myocardial damage, including myoglobin, CK-MB or troponin-I were found (Fig 6).
Effects of treatments on EPCs and CECs
In patients treated with ezetimibe and/or high-dose statins, the change of mean number of
EPCs-CFUs/plate and EPCs-ECFCs/plate (Fig 6), as well as in any parameter of EPC-ECFC
tubulization activity (Fig 6), were all non-significant compared with placebo (for all, p>0.05).
Lipid-lowering agents, CECs and EPCs
PLOS ONE | https://doi.org/10.1371/journal.pone.0172800 April 10, 2017 9 / 18
Changes in EPC-CFU-EC and EPCs-ECFC levels, and in any parameter of tubulization activ-
ity of EPCs-ECFCs as the result of treatments (after treatment–before treatment = Δ) were
non-significant (p>0.05). In patients treated with ezetimibe and/or high-dose statins there was
a trend towards an increase of EPC level after active treatments as compared with placebo, but
this was not statistically significant. This trend was however only observed in patients treated
with high-dose rosuvastatin or the rosuvastatin+ezetimibe combination, and not in the atorva-
statin group.
For flow cytometry analyses, a gating strategy was used, by which events displaying any
lymph-monocyte morphology, alive and nucleated, were firstly gated, while dead cells and
non-nucleated events were excluded in order to remove non-specific signals. Alive and nucle-
ated lymph-monocyte cells were then analyzed for their expression of CD34 and CD45. Two
different levels of CD34 surface expression allowed the identification of distinct CD34+ cell
subpopulations. A subset of CD34+/CD45dim cells, matching the antigen profile of HSC, and a
more restricted subpopulation of cells expressing bright levels of CD34 and resulting to be
CD45 negative, were detected. Subsequently, cells staining positive or bright for CD34 and
dim or negative for CD45 were analyzed for the endothelial cell markers CD144, 146 and
CD309. We found no significant changes as the result of treatments between the absolute
numbers of all CD34+/CD45- events (Fig 6) or CECs (CD34bright/CD45-/CD144+/CD146+)
(Fig 6), or HSC (Fig 6) in the ezetimibe and/or high-dose statin treatments, and no significant
differences vs the placebo group. Furthermore, all subsets of CD34+/CD45- cells, negative for
CD144, CD146 and CD309 (Fig 6), or resulting from the different combinations of CD144,
Fig 5. Baseline characteristics of the population studied, divided in the various study groups. Abbreviations: SD = standard deviation;
CAD = coronary artery disease; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; CAD = coronary artery disease.
https://doi.org/10.1371/journal.pone.0172800.g005
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CD146 and CD309 (Fig 6) did not show any significant differences in any of the active treat-
ment groups, or in the placebo group.
We also found overall no correlation between differences (Δ = after minus before treat-
ments) of EPC numbers and activity (according to cell culture method) and differences (Δ =
after minus before treatments) of plasma levels of CECs according to flow cytometry methods
here used, with the exception of 3 (out of 126) correlation coefficients (Fig 7).
Discussion
Contrary to the study hypothesis and to previous findings about an acute increase of EPCs/
CECs after high-dose lipid lowering treatments, we here found no evidence of any significant
change in either the number or the functional activity of such cells after an acute lipid-lowering
treatment. These results were obtained adopting a number of complementary techniques for
the identification of circulating progenitors, and in the unprecedented setting of a double-
blind, randomized, placebo-controlled study.
Since the acute pre-procedural administration of statins has been associated with cardio-
and renal protection, including reduced release of myocardial necrosis markers [22] and
reduced incidence of contrast media-induced acute kidney injury [35], the hypothesis that
some of these effects may be contributed by an acute mobilization of circulating progenitors
Fig 6. Selected markers of myocardial damage, parameters of angiogenesis and clonogenic activities, and surface antigens before and after
treatment. For each parameter, at each time point, numbers represent the median and the interquartile range (this latter in parenthesis). Abbreviations;
Plac = placebo; At80+40 = atorvastatin 80 mg + 40 mg; Ro40+40 = rosuvastatin 40 mg + 40 mg; RoEz = rosuvastatin + ezetimibe (these are the treatment
groups as defined in Methods); T0, T1 = time 0, time 1, as defined in Methods; Δ T1-T0 = Difference T1-T0; CK-MB = creatine kinase-MB isoform; Early
and Late Colonies = as defined in Methods; CD = cluster of differentiation—see Methods for details.
https://doi.org/10.1371/journal.pone.0172800.g006
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had attracted considerable interest. Nevertheless, results from the studies of EPCs and statins
in the context of periprocedural myocardial injury, such as during and after PCI, have yielded
quite equivocal or discordant results [36]. This may reflect on the one hand the quality of the
experimental setting in which such hypotheses were tested; and, on the other hand, the varying
manner by which EPCs had been quantified.
There are two possible ways to identify and characterize EPCs: by flow cytometry, looking
at cell surface antigenic markers; and by cell culture methods, looking at their functional activi-
ties (reviewed in [37]). Currently, 3 main cell culture methods are used to identify 3 types of
EPCs with different functions and angiogenic potential: late outgrowth colonies, also known
as ECFCs, which are considered as genuine or true EPCs [30]; colony-forming unit (CFU)-
Hill cells [28]; and early outgrowth EPCs, also known as circulating angiogenic cells (CACs)
[38] (reviewed in [37]). ECFCs display a high proliferative potential, express endothelial anti-
gens, form capillary-like structures when plated on Matrigel, but also blood vessels when sus-
pended in collagen or Matrigel scaffolds and implanted in immunodeficient mice (reviewed in
[37]). CFU-Hill cells and CACs display a low proliferative potential, but a great potential to
secrete an array of angiogenic cytokines. CFU-Hill cells and CACs are positive for CD45,
CD34, CD31 and KDR, and have the capacity to uptake uptake acetylated LDL labeled with
1,1’-dioctadecyl-3, 3, 3’, 3’-tetramethyl-indocarbocyanine perchlorate (DiDLDL)) [37]. As to
the identification and enumeration of EPCs by flow cytometry, EPC antigenic profile contin-
ues to be controversial [33, 39], and no consensus guidelines have been agreed upon so far [39,
40]. Therefore, in the present study we decided to analyze CECs by flow cytometry, for which
there is at least some agreement in identifying such cells as CD34bright/CD45-/CD144+/
CD146+ events, together with DNA staining and dead cell exclusion [33, 41]. CECs are charac-
terized by mature endothelial features and detach from the vessel walls following vascular
damage or because of their physiological turnover [42, 43]. Their levels in peripheral blood
Fig 7. Correlation analysis (Spearman rho) of the differences (Δ = after minus before treatments) in angiogenesis and clonogenic activities
(independent variable), and the differences (Δ = after minus before treatments) in surface antigens. Abbreviations; AU = Arbitrary Units; Early (A)
and early (B) = Hill colony analysis performed by two independent investigators. Only the underlined correlation coefficients were significant.
Treaments = atorvastatin 80 mg + 80 mg, rosuvastatin 40 mg + 40 mg, rosuvastatin 10 mg + ezetimibe 10 mg.
https://doi.org/10.1371/journal.pone.0172800.g007
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have been reported as decreased after statin treatment [44]. Similarly as for EPCs, CEC charac-
terization and enumeration in the bloodstream has been proposed as a potential biomarker of
the response to treatment in several clinical conditions involving vascular damage, regenera-
tion and growth [4, 41, 45–47]. Likewise, preclinical and clinical studies have suggested that
EPCs play an essential role in neovascularization, and are biomarkers of atherosclerosis,
inversely related to the presence and progression of the disease (reviewed in [37]).The balance
of CEC and EPC levels would reflects the endothelial health status [43, 48].
We examined whether the reported beneficial effect of statins in reducing periprocedural
myocardial injury is due to their effects on EPCs. We also addressed the important question of
whether this is a class effect or, on the contrary, differences exist between rosuvastatin, atorva-
statin and the low-dose rosuvastatin/ezetimibe combination. These 3 treatments were selected
because achieving similar effects on LDL lowering on chronic treatment. While the first two
treatments determine a robust LDL lowering through a substantial inhibition of HMGCoA
reductase [49], the third does so by combining a relatively milder HMGCoA reductase inhibi-
tion with an interference in LDL intestinal absorption with ezetimibe [50, 51]. The setting of
the REMEDY trial, by which these 3 active treatments were compared with placebo in a dou-
ble-blind double-dummy design, overcomes several of the methodological biases attributable
to less rigorous study design, as adopted in virtually all previous studies on this topic. This
report addresses the possible impact of tested regimens on early EPC levels and functional
activity; another report will deal with longer-term (3-months) effects [23].
Here we prospectively investigated whether the preprocedural exposure to different lipid-
lowering drugs (statins and/or ezetimibe) or placebo can acutely (within 24 h) modify levels of
CECs and levels and functional activity of EPCs, with potential differences between treatments.
While it is generally recognized that statin administration to patients may increase levels of
EPCs, identified by varying combinations of surface antigens, in the absence of accepted
guidelines [39, 40], the time- and dose-response course of such effects by different lipid-lower-
ing agents had not been previously characterized. Our study is therefore the first attempt to
assess functional and antigenic levels of EPCs after the acute administration of various lipid-
lowering agents, prospectively administered with random allocation and in a double-blind
design. In addition, this is the first study attempting to enumerate CECs and any subsets of
CD34+/CD45- cells, deriving from several combination of endothelial markers (CD144,
CD146 and CD309), by flow cytometry in the peripheral blood of CAD patients.
Our data show that the acute (within 24 h) preprocedural administration of different lipid-
lowering drugs, at higher doses compared with the usual-doses administered before an elective
PCI, is not associated with any evidence of EPC mobilization and/or of any release of CACs
from the vessel wall in the peripheral blood, without any differences between either treatments
and placebo or among the various treatment here tested. Recently, CECs have been found to
define a population of mature endothelial cells, that detach from the vessel walls, following vas-
cular damage or its physiological turnover, and become circulating cells [42, 43]. However,
data about the acute effects of statin treatment and PCI on EPCs are debatable, reflecting the
heterogeneity of methods used for the evaluation of EPCs and the great variability in statin
treatment timing and dosage [36]. Vasa et al. [11] demonstrated, in a series of 15 patients with
stable CAD, that a therapy with atorvastatin 40 mg/day increased the number and functional
activity of EPCs after 1 week of treatment. More recently, it has been suggested that the effect
on EPC mobilization might be dose-dependent: among 100 patients with ischemic heart dis-
ease; here treatment with atorvastatin 40 mg/day was associated with a higher EPC level than a
regimen of atorvastatin 10 mg/day [52]. At the same time, other groups have shown that
chronic statin therapy can be associated with a reduced–rather than increased–EPC number
and function. So, Hristov et al. found that a chronic (3-month) statin treatment was associated
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with a reduction in the number of circulating EPCs. The dose of continuous statin therapy
inversely correlated with EPC number, and patients treated with a 40 mg/day statin (simva-
statin or atorvastatin) showed a reduction in EPC number. Interestingly, statin treatment did
not affect the functional properties of EPCs tested by the CFU-Hill Assay [53]. Conversely,
Deschaseaux et al. found that the number of EPC colonies after 5 days of culture was lower in
patients on chronic statin treatment (here with 40 mg/day of pravastatin or simvastatin for at
least 4 weeks) compared with those without statin therapy, while long-term statin treatment
would preserve late EPC colonies [54]. Recently, a systematic review of preclinical and clinical
studies on statin and EPCs [55] reported two clinical studies examining the effect of statin
therapy on EPC levels in CAD patients [56, 57]. One study used atorvastatin and the other
used rosuvastatin. One study showed an increase in circulating levels of EPCs after 5 days of
statin therapy and the other reported greater numbers of CFU-Hill after 6 months of treat-
ment. However, the non-randomized nature of most of these studies and the lack of standard
dosing certainly justifies uncertainty in drawing firm conclusions. Data from randomized
studies of both early and long-term effects of statin therapy on EPCs are therefore clearly war-
ranted. Our report tries to fill-in such knowledge gap with an appropriate study design and
multiple methods to detect and quantify EPCs and CACs. We found no evidence of any acute
effect of lipid-lowering therapies on any of the parameters here investigated. We also report no
correlations of antigenic vs functional parameters for EPC/CEC assessment (with only 3 out of
126 correlation coefficients turning out to be “statistically significant”, but with no adjustment
for multiple testing, which we therefore attribute to the play of chance), casting doubts on the
possibility of using such parameters interchangeably in future studies.
Study limitations
We recognize limitations of our study. Given the relatively small patient population, we cannot
rule out the occurrence of a Type 2 statistical error. However, the combination of high statin
dose (atorvastatin and rosuvastatin) does not here provide a signal for efficacy, nor such a sig-
nal appears even combining the 3 active treatment groups or the similarly acting, atorvastatin
and rosuvastatin, with similar potency.
As a second limitation, no data are here available about the EPC behavior in a prolonged
follow-up. This was beyond the specific objectives of the present REMEDY-EPC early sub-
study, but will be the subject of an independent report (the REMEDY-EPC late substudy), as
also obtained in a different patient population and in another research center, within the same
overall REMEDY study.
Because of the short time of the observation, no independent effects of any of the acute
treatment administered could be demonstrated. We did not measure changes in lipid parame-
ters or CRP, clearly shown upon longer treatments [58], as such changes are not expected to
occur so acutely. The occurrence of acute administration was however witnessed by the inves-
tigators involved, and we can reasonably exclude issues of non-compliance. We did not find
any effect of treatments on indices of myocardial damage, suggesting at least no harm from
such treatments. The main aim of this pilot study was to provide descriptive data that can be
valuable in designing future trials
Conclusions
Our data, the first obtained after randomization of patients to multiple types of lipid-lowering
drugs and at different dosage, and assessing CEC and EPC levels and functional activity, argue
for the absence of any mechanistic link between any otherwise observed clinical outcome
(observed in other studies) and the effects of early statin therapy on EPCs/CACs in patients
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with CAD. The absence of any increase in EPC levels and function, whathever the type and
dosage of lipid-lowering agent used, appears to reinforce the concept that any beneficial effect
of early therapy with lipid-lowering drugs on periprocedural myocardial injury at PCI would
be concomitant–and therefore also possibly linked–with the lowering of LDL cholesterol lev-
els, which would require a longer time course, rather than to pleiotropic effects, at least those
due to the mobilization of EPCs. This is in line with our findings explaining the effects of stat-
ins on stroke largely as the result of LDL cholesterol lowering, in a separate analysis of lipid-
lowering clinical trials [59, 60].
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